Discovery and development of compounds that help to modify the progression of neurological and/or neurodegenerative diseases, particularly in the Alzheimer’s disease
Approaches this kind of diseases focusing on the early stages of them, pointing out innovative therapeutic targets supported by translational research. This strategy is a distinctive feature compared to research lines developed by pharmaceutical companies to date.
There are 5 new patented neuroprotective compounds against Alzheimer’s and epilepsy in its portfolio that belong to three different pharmacological groups. It also has a broad molecule and high-value added microbial extracts collection (>22,000).
Furthermore, Neuron Bio has developed a drug discovery and development platform that brings together more than 50 differentiating technologies.
